Tuning of the Aggregation Behavior of Fluorinated Polymeric Nanoparticles for Improved Therapeutic Efficacy
Source abstract
Abstract
Incorporation of fluorinated moieties in polymeric nanoparticles has been shown in many instances to increase their uptake by living cells and, hence, has proven to be a useful approach to enhancing delivery to cells. However, it remains unclear how incorporation of fluorine affects critical transport processes, such as interactions with membranes, intracellular transport, and tumor penetration. In this study, we investigate the influence of fluorine on transport properties using a series of rationally designed poly(oligo(ethylene glycol) methyl ether acrylate)-block-perfluoropolyether (poly(OEGA)m-PFPE) copolymers. Copolymers with different fluorine contents were prepared and exhibit aggregate in solution in a manner dependent on the fluorine content. Doxorubicin-conjugated poly(OEGA)20-PFPE nanoparticles with lower fluorine content exist in solution as unimers, leading to greater exposure of hydrophobic PFPE segments to the cell surface. This, in turn, results in greater cellular uptake, deeper tumor penetration, as well as enhanced therapeutic efficacy compared to that with the micelle-state nanoaggregates (poly(OEGA)10-PFPE and poly(OEGA)5-PFPE) with higher fluorine content but with less PFPE exposed to the cell membranes. Our results demonstrate that the aggregation behavior of these fluorinated polymers plays a critical role in internalization and transport in living cells and 3D spheroids, providing important design criteria for the preparation of highly effective delivery agents.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Polymer Synthesis and Characterization · Polymer Surface Interaction Studies · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Materials Research Laboratory, University of California, Santa Barbara, California 93106, United States
QIMR Berghofer Medical Research Institute, Brisbane, Qld 4006, Australia
Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois 60612, United States
Funding
National Health and Medical Research Council · Australian Research Council · Division of Materials Research · University of Queensland
References (54)
Show source-provided references
1. 10.7150/thno.1970410.7150/thno.19704 ↗
2. 10.1021/ja902777d10.1021/ja902777d ↗
3. 10.1039/C6PY02204A10.1039/C6PY02204A ↗
4. 10.1002/anie.20191411910.1002/anie.201914119 ↗
5. 10.1021/acs.biomac.9b0024110.1021/acs.biomac.9b00241 ↗
6. 10.1021/acs.bioconjchem.6b0021610.1021/acs.bioconjchem.6b00216 ↗
7. 10.1021/acscentsci.5b0023310.1021/acscentsci.5b00233 ↗
8. 10.1007/s12156-011-0074-310.1007/s12156-011-0074-3 ↗
9. 10.1002/cbic.20030102310.1002/cbic.200301023 ↗
10. 10.1002/chem.20170291710.1002/chem.201702917 ↗
11. 10.1021/acsmacrolett.8b0043310.1021/acsmacrolett.8b00433 ↗
12. 10.1016/j.tetlet.2017.12.03210.1016/j.tetlet.2017.12.032 ↗
13. 10.1021/acs.macromol.8b0119010.1021/acs.macromol.8b01190 ↗
14. 10.1039/C7PY00986K10.1039/C7PY00986K ↗
15. 10.1002/advs.20200040610.1002/advs.202000406 ↗
16. 10.1021/acs.joc.5b0161410.1021/acs.joc.5b01614 ↗
17. 10.1093/nar/gkl06110.1093/nar/gkl061 ↗
18. 10.1021/acs.biomac.6b0178810.1021/acs.biomac.6b01788 ↗
19. 10.1163/156856299X0014410.1163/156856299X00144 ↗
20. 10.1038/ncomms405310.1038/ncomms4053 ↗
21. 10.1021/acs.macromol.7b0128510.1021/acs.macromol.7b01285 ↗
22. 10.1021/acsnano.8b0372610.1021/acsnano.8b03726 ↗
23. 10.1002/smll.20190230910.1002/smll.201902309 ↗
24. 10.1021/acs.biomac.8b0154910.1021/acs.biomac.8b01549 ↗
25. 10.1021/jacs.0c0402810.1021/jacs.0c04028 ↗
26. 10.1016/j.jallcom.2018.03.35510.1016/j.jallcom.2018.03.355 ↗
27. 10.1039/C8DT02436G10.1039/C8DT02436G ↗
28. 10.1039/C9TB01509D10.1039/C9TB01509D ↗
29. 10.1016/j.biomaterials.2017.07.00410.1016/j.biomaterials.2017.07.004 ↗
30. 10.1039/C4PY00999A10.1039/C4PY00999A ↗
31. 10.1002/mrm.2545410.1002/mrm.25454 ↗
32. 10.1039/C8NR00703A10.1039/C8NR00703A ↗
33. Zhang C. · J. Nanosci. Nanomed. · 2018 · 2 · 19
34. 10.1021/acs.macromol.5b0241410.1021/acs.macromol.5b02414 ↗
35. 10.1021/acssensors.6b0021610.1021/acssensors.6b00216 ↗
36. 10.1021/acs.macromol.5b0064110.1021/acs.macromol.5b00641 ↗
37. 10.1039/C5SM00287G10.1039/C5SM00287G ↗
38. 10.1038/ncomms548210.1038/ncomms5482 ↗
39. 10.1038/nnano.2016.16010.1038/nnano.2016.160 ↗
40. 10.1038/nchem.12010.1038/nchem.120 ↗
41. 10.1016/S0006-3495(93)81075-010.1016/S0006-3495(93)81075-0 ↗
42. 10.1016/j.bios.2016.07.02610.1016/j.bios.2016.07.026 ↗
43. 10.1039/C5CP05056A10.1039/C5CP05056A ↗
44. 10.1039/c2cp40200a10.1039/c2cp40200a ↗
45. 10.1016/S0968-0004(01)02003-510.1016/S0968-0004(01)02003-5 ↗
46. 10.1039/C4NR02100B10.1039/C4NR02100B ↗
47. 10.1039/C7PY00385D10.1039/C7PY00385D ↗
48. 10.1021/nn506928p10.1021/nn506928p ↗
49. 10.1021/ci300363c10.1021/ci300363c ↗
50. 10.1021/ci300364910.1021/ci3003649 ↗
51. 10.1016/S0006-3495(97)78259-610.1016/S0006-3495(97)78259-6 ↗
52. 10.1002/jcc.2028910.1002/jcc.20289 ↗
53. 10.1063/1.46439710.1063/1.464397 ↗
54. 10.1002/jbm.a.3479710.1002/jbm.a.34797 ↗